The Bard hernia mesh failure mass tort litigation represents one of the largest medical device settlements in recent history, with a global settlement agreement exceeding $1 billion established in October 2024 against Becton, Dickinson and Company (BD). This litigation consolidated approximately 38,000 to 40,000 lawsuits from patients who suffered serious complications from defective hernia mesh products manufactured by Bard, resulting in a structured compensation program designed to provide financial relief to affected individuals. The case is being handled as MDL-2846 in federal court in Ohio, with thousands of claims still active and new cases continuing to be filed. Patients who received Bard hernia mesh implants—including products like Bard Ventralight, Bard Ventralex, Bard Perfix Plug, and Bard 3D Max—have experienced severe complications ranging from mesh migration and infection to chronic pain and recurrent hernias requiring additional surgeries.
For example, one Rhode Island man received a $4.8 million verdict after undergoing multiple corrective surgeries for gastrointestinal injuries caused by complications from his Bard Ventralex hernia mesh. These weren’t isolated incidents; the litigation encompasses a pattern of device failures that affected tens of thousands of people across the United States who believed they were receiving safe, approved medical treatment. The settlement process has established a Qualified Settlement Fund administered by Wells Fargo, with compensation determined through a points-based system that accounts for the specific severity of injuries and long-term health impacts rather than offering uniform payouts to all claimants. Understanding your rights in this litigation and how to pursue compensation is critical if you received one of these defective mesh products.
Table of Contents
- What Happened with Bard Hernia Mesh Products?
- The Scale of the Settlement and How It Was Structured
- How Much Compensation Are Claimants Receiving?
- Who Can File a Claim and What’s the Process?
- Common Complications from Bard Hernia Mesh Failures
- The Evidence Against Bard
- Current Status and Future Outlook
- Conclusion
What Happened with Bard Hernia Mesh Products?
Bard’s hernia mesh products were marketed as solutions for patients requiring hernia repair, a common surgical procedure performed hundreds of thousands of times each year in the United States. However, clinical evidence and patient experiences revealed that these mesh products were prone to serious failures that Bard either knew about or should have known about. The polypropylene material used in many Bard mesh products could migrate within the body, adhere to surrounding tissue and organs, trigger chronic inflammatory responses, and degrade over time, leading to recurrent hernias and requiring patients to undergo additional surgical interventions. The problems with these products became evident when patients began reporting complications at higher rates than would be expected for hernia mesh generally.
While hernia mesh complications overall occur in a meaningful but manageable portion of patients—hernia mesh infection rates range from 1-8% depending on the surgical approach, with ventral hernia repairs showing infection rates in the 1-8% range—patients with Bard products appeared to experience complications at elevated rates. Additionally, chronic pain affected approximately 10-30% of post-hernia surgery patients, and hernia recurrence rates of 3-5% for inguinal hernias and higher rates for ventral hernias suggested manufacturing or design defects specific to Bard’s products. The litigation alleged that Bard knew or should have known about these failure rates but failed to adequately warn patients and surgeons about the risks, continued marketing the products as safe and effective, and prioritized profits over patient safety. This pattern of alleged misconduct forms the foundation of the mass tort claims.
The Scale of the Settlement and How It Was Structured
The October 2024 settlement agreement representing more than $1 billion in total value reflects the severity and breadth of the problems with Bard’s hernia mesh products. This isn’t a token settlement—it’s one of the largest medical device settlements in U.S. history and demonstrates how seriously the courts and settlement negotiations treated the injuries and complications experienced by hernia mesh recipients. The settlement resolves approximately 38,000 to 40,000 lawsuits, though notably, as of April 2026, there are still 26,297 active pending cases in the hernia mesh litigation, meaning tens of thousands of additional claimants continue to pursue compensation outside the original settlement. The settlement established a Qualified Settlement Fund to manage payouts in an organized, structured manner.
Wells Fargo was selected to manage this account, with funds deposited into an escrow account overseen by special masters and lien administrators. This structure protects claimants by ensuring that compensation money is held securely and distributed according to a predetermined process rather than through informal arrangements that could lead to disputes or defaults. The QSF framework also allows for the careful administration of liens—claims from health insurance companies, Medicare, and Medicaid for reimbursement of medical expenses they paid for mesh-related complications. One important limitation to understand: not all injured parties may be eligible for the settlement, and the eligibility criteria can be complex. Parties needed to have received a Bard mesh product and developed qualifying complications during a specific timeframe. Additionally, the settlement value of more than $1 billion must be divided among tens of thousands of claimants, meaning individual awards, while substantial, are not unlimited.
How Much Compensation Are Claimants Receiving?
The settlement uses a points-based compensation system that determines awards based on the specific severity of each person’s injuries and long-term health impacts. Rather than offering a flat payment to all claimants, the system recognizes that some people suffered more severe complications requiring multiple surgeries, chronic pain management, significant lifestyle disruption, and ongoing medical care, while others experienced less debilitating complications. This approach, while more equitable than a uniform payout, requires careful documentation of medical records and careful evaluation of each claim. Average settlements range from $60,000 to $100,000, with higher amounts awarded for severe cases. For example, one claimant in Ohio received a $255,000 verdict when a jury found that his hernia mesh had adhered to his abdominal wall, causing serious infections and a bowel abscess requiring extensive treatment.
On the higher end, the $4.8 million verdict to the Rhode Island man with gastrointestinal injuries demonstrates that in cases involving severe, permanent complications, awards can substantially exceed the average range. However, it’s important to recognize that verdicts and settlement awards vary widely based on case-specific factors, medical evidence, jurisdiction, and negotiating positions. The points system evaluates factors such as the type of Bard product received, the specific complications experienced, the number of revision surgeries required, the presence of chronic pain or other long-term health effects, and the impact on quality of life. Claimants with severe complications requiring multiple surgeries and resulting in permanent disability score higher in the points system and receive larger awards, while those with less severe complications receive proportionally smaller compensation. Documentation of all medical treatment related to mesh complications is critical to establishing the severity of your claim.
Who Can File a Claim and What’s the Process?
Eligibility for the Bard hernia mesh settlement generally requires that you received a Bard hernia mesh product and subsequently developed complications related to that product. The eligible Bard products include Bard Ventralight, Bard Ventralex, Bard Perfix Plug, Bard 3D Max, and other polypropylene mesh products manufactured by Bard. You’ll need medical documentation establishing that you received one of these products and that you experienced qualifying complications such as infection, mesh migration, adhesions, chronic pain, or recurrent hernia requiring revision surgery. The filing process typically begins with completing a claim form that requests detailed information about your medical history, the original hernia repair surgery, your complications, subsequent treatments, and the impact on your life. You’ll need to gather medical records from the surgery that placed the mesh, any hospitalizations or emergency room visits related to complications, records of revision surgeries, pain management treatment, and any other medical documentation supporting your claim.
Many claimants work with attorneys who specialize in mass tort litigation to evaluate their cases, gather necessary documentation, and navigate the claims process. The settlement website and claim administrator provide instructions for filing, including deadlines that vary depending on the specific settlement structure. One important tradeoff: while working with an attorney increases the likelihood of a successful claim and helps ensure you understand your options, attorneys typically take a contingency fee (usually 25-40% of your settlement award plus court-approved costs). This means you won’t pay upfront, but your net recovery will be reduced by the attorney’s fee. For some claimants with less severe injuries resulting in smaller awards, this fee structure might mean limited net recovery even if the claim succeeds. Comparing potential outcomes and discussing fee structures with multiple attorneys can help you make an informed decision.
Common Complications from Bard Hernia Mesh Failures
The most frequently reported complications from Bard hernia mesh failures include mesh infection, mesh migration or positioning problems, adhesions (where mesh adheres to surrounding tissue and organs), and chronic pain. Mesh infections can range from superficial surgical site infections to deep tissue infections involving the mesh itself and surrounding abdominal organs. These infections often require hospitalization, broad-spectrum antibiotics, and frequently require surgical intervention to remove or revise the infected mesh. A common warning sign that physicians and patients should recognize: fever, increasing pain or swelling at the surgical site, or signs of systemic infection weeks or months after the original surgery may indicate a mesh infection. Adhesions represent another serious complication where the mesh or scar tissue from the surgical repair adheres to abdominal organs, intestines, or other structures within the abdomen.
This can cause pain, bowel obstruction, and difficulty with subsequent surgeries. In some cases, adhesions develop years after the original surgery, causing chronic symptoms that substantially reduce quality of life. The case of the Ohio man whose hernia mesh adhered to his abdominal wall, resulting in a serious infection and bowel abscess, exemplifies how adhesions can cascade into life-threatening complications requiring extensive treatment. Chronic pain following hernia surgery affects approximately 10-30% of patients post-surgery, and some litigation claimants experienced debilitating chronic pain lasting years after their original repair. Additionally, hernia recurrence—where the hernia returns despite the mesh repair—occurred at rates higher than would be expected, with some patients requiring multiple revision surgeries. These complications weren’t one-off events; the pattern across tens of thousands of cases suggests systemic problems with product design, manufacturing, or the material itself.
The Evidence Against Bard
The litigation against Bard rested on evidence that the company either knew or should have known about the elevated failure rates of its hernia mesh products. Internal company documents, clinical data, adverse event reports submitted to the FDA, and post-market surveillance information all contributed to the case against the manufacturer. The fact that Bard continued marketing these products as safe and effective despite mounting evidence of problems formed a key part of the allegations.
Comparative data on hernia mesh complications proved particularly important. While some complications are inherent to hernia mesh technology generally, the rates of complications from Bard products appeared to exceed those of competing products from other manufacturers, suggesting a specific problem with Bard’s design or manufacturing. This comparative evidence, combined with the sheer number of cases filed—tens of thousands across the United States—created a compelling picture of a defective product that harmed a large population.
Current Status and Future Outlook
As of April 2026, more than two years after the settlement agreement was reached, the litigation continues to evolve. While the October 2024 settlement resolved approximately 38,000 to 40,000 cases, an additional 26,297 claims remain pending in hernia mesh class action lawsuits and MDL-2846 as of April 2026. In fact, cases continue to be added to the litigation—by June 2026, there were 25,015 active cases in MDL-2846, indicating that new claimants are still discovering their injuries and joining the litigation.
This ongoing addition of claims suggests that patients continue to experience Bard mesh complications and that awareness of the litigation and settlement options is still spreading. For individuals who received a Bard hernia mesh product years ago and are now experiencing problems, or for those who recently learned about the litigation, the litigation remains an active avenue for seeking compensation. However, the window for filing claims is not indefinite, and deadlines established in the settlement agreement must be met. Anyone who believes they may be eligible should investigate their options promptly, as delays could affect eligibility or available compensation.
Conclusion
The Bard hernia mesh failure mass tort litigation represents a significant accountability moment for a major medical device manufacturer and a vehicle for compensation for tens of thousands of patients who suffered serious complications from defective products. With a settlement exceeding $1 billion, a structured compensation system using a points-based approach, and ongoing claims administration through a Qualified Settlement Fund, the litigation has provided a mechanism for injured parties to recover compensation for their medical expenses, pain and suffering, lost wages, and reduced quality of life. Individual awards range from tens of thousands to millions of dollars depending on the severity of complications, though the average settlement falls in the $60,000 to $100,000 range.
If you received a Bard hernia mesh product and have experienced complications such as infection, mesh migration, adhesions, chronic pain, or hernia recurrence, you may be eligible for compensation under the settlement or through ongoing litigation. The next step is to gather your medical records documenting both your original mesh implantation and your subsequent complications, review the eligibility criteria with a qualified attorney or the claim administrator, and file a claim before applicable deadlines expire. With over 26,000 cases still pending as of April 2026 and new claims continuing to be added, the litigation remains active, but the window for participation is not unlimited.